Saturday 17 October 2026 Export TARA’s income statement to Excel — free account

Protara Therapeutics, Inc.

In the quarter to June 2026, EPS fell 2.86% and free cash flow fell 28.1%, each against the same quarter a year earlier.

2.33 0.07 −2.92%

Follow TARA

Alert me

Market cap: $141.8M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: 7.27
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	2	—	1	—	—	—	—

Insider Ownership 14.45%

Capital & Financial Ratios $m

Market Cap 141.83

Revenue —

Net Income (70.01)

Free Cash Flow (66.52)

Net Debt (142.49)

Current Ratio 10.97

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.88

Past 5Y EPS Growth —

This Y EPS Growth (3.52%)

Next Y EPS Growth (17.82%)

Next Y revenue growth —

Next 5Y EPS Growth 23.07%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 54.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	66	170	156	142
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	69	172	160	146

	2023	2024	2025	Q'26
Payables	2	4	3	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	6	11	11	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	11.97%	(0.29%)	24.38%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(15)	—	—	—
’25	(15)	(12)	(12)	(17)	(56)
’24	(10)	(8)	(8)	(9)	(36)
’23	(13)	(9)	(7)	(9)	(38)
’22	(11)	(5)	(5)	(5)	(26)
’21	(12)	(9)	(6)	(7)	(35)
’20	(7)	(6)	(4)	(7)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(16)	—	—	—
’25	(15)	(12)	(12)	(17)	(56)
’24	(10)	(8)	(8)	(9)	(36)
’23	(13)	(9)	(7)	(9)	(38)
’22	(11)	(5)	(5)	(5)	(27)
’22	—	—	—	—	(26)
’21	(12)	(10)	(6)	(7)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.31)	(0.36)	—	—	—
’25	(0.29)	(0.35)	(0.31)	(0.37)	(1.34)
’24	(0.97)	(0.45)	(0.50)	(0.48)	(2.17)
’23	(0.80)	(1.00)	(0.87)	(0.90)	(3.57)
’22	(0.96)	(0.80)	(0.68)	(3.46)	(5.86)
’21	(1.20)	(1.14)	(0.96)	(0.91)	(4.21)
’20	(1.81)	(1.22)	(1.26)	(0.79)	(4.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	70.00	44.00	60.00	8.80	15.86	5.94	2.38	1.04	1.60	2.77	Analyst estimates 2026–2028 Powerpack
	High	600.00	110.00	116.00	157.60	67.08	25.20	7.15	4.18	10.48	7.82
People
People	Employees	19	16	17	12	29	32	25	27	33	51
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(29)	(30)	(21)	(8)	(34)	(47)	(66)	(40)	(45)	(57)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(29)	(30)	(21)	(8)	(34)	(47)	(66)	(40)	(45)	(57)
	Depreciation	0	0	0	0	0	3	32	0	0	(1)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(68.80)	(85.20)	(46.00)	(3.04)	(4.70)	(4.21)	(5.86)	(3.57)	(2.17)	(1.34)
	Cash flow	(57.20)	(51.75)	(51.33)	(1.94)	(3.24)	(3.07)	(2.35)	(3.31)	(1.74)	(1.32)
	Capex	(0.65)	(0.08)	(0.26)	(0.18)	(0.12)	(0.05)	(0.01)	0.00	0.00	0.00
	Free cash flow	(57.86)	(51.83)	(51.60)	(2.13)	(3.36)	(3.12)	(2.36)	(3.32)	(1.74)	(1.32)
	Book value	92.83	80.43	45.17	(0.83)	27.54	14.41	9.07	6.03	8.12	4.59
	Shares, m	0	0	0	3	7	11	11	11	21	43
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(24)	(22)	(23)	(5)	(23)	(35)	(26)	(38)	(36)	(56)
	Capex	0	0	0	0	(1)	(1)	0	0	0	0
	Free cash flow	(24)	(22)	(23)	(5)	(24)	(35)	(27)	(38)	(36)	(56)
Balance, $m
Balance, $m	Working capital	38	34	20	(3)	167	89	80	63	161	149
	Total debt	—	—	—	—	1	7	6	—	—	—
	Net debt	(41)	(42)	(22)	(1)	(169)	(91)	(84)	(66)	(170)	(156)
	Shareholders’ equity	38	35	20	(2)	199	162	102	68	167	196
Returns, %
Returns, %	ROA	(51.37)	(83.91)	(61.42)	(63.29)	(33.25)	(25.15)	(46.14)	(42.05)	(34.25)	(29.39)
	ROIC	0.00	0.00	0.00	0.00	(70.36)	(41.99)	(236.63)	(994.46)	0.00	(98.74)
	ROE	(56.02)	(142.13)	(341.61)	488.15	(34.48)	(26.17)	(49.96)	(47.44)	(37.88)	(31.60)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2014 · latest quarter Sep 2014

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MENS Jyong Biotech Ltd.	$147.0M	—	—	—	—	—	—	—	Compare
MSLE Satellos Bioscience Inc.	$145.1M	— (loss-making)	—	—	n/m	−65.66% (below 0%: shrinking)	99.26%	0.00%	Compare
MOLN Molecular Partners AG Sponsored ADR	$143.5M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+23.77% (above 0%: growing)	0.00%	0.00%	Compare
TARA Protara Therapeutics, Inc.	$141.8M	— (loss-making)	—	—	n/m	−28.10% (below 0%: shrinking)	0.00%	0.00%
ALXO ALX Oncology Holdings Inc.	$138.3M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+31.65% (above 0%: growing)	0.00%	0.00%	Compare
NKTX Nkarta, Inc.	$138.2M	— (loss-making)	—	—	n/m	−29.19% (below 0%: shrinking)	0.00%	0.00%	Compare
AVXL Anavex Life Sciences Corp.	$137.2M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%	Compare
KRRO Korro Bio, Inc.	$137.1M	— (loss-making)	— (loss-making)	−86.28% (below 0%: shrinking)	n/m	+12.07% (above 0%: growing)	100.00%	0.00%	Compare
ANTX AN2 Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	+7.91% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$138.3M	—	—	−98.86%	—	+12.07%	0.00%	0.00%

All 614 Biotechnology stocks →

Protara Therapeutics, Inc. (TARA) key facts

Protara Therapeutics, Inc. (TARA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TARA traded at $2.33, a market capitalization of $141.8 million.
Return on equity was −31.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.